Lilly factory in New Jersey comes under more federal scrutiny
Lilly said it was working closely with the FDA and the “situation does not affect the quality, safety or supply of any current or planned Lilly products in the marketplace.”
John Russell
Articles
Indiana not-for-profits pulled in $348.7 million in big gifts in 2023
Universities, hospitals, museums, theaters, dance companies and other not-for-profits in Indiana pulled in a total of $348.7 million from 79 gifts of $1 million or more from individuals, family foundations and bequests, according to IBJ’s latest survey.
Move away from coal could be slowed under Indiana bill
State Rep. Cindy Ledbetter introduced the bill this month, saying utilities are moving too fast to retire and replace generating capacity that might be needed as demand for electricity grows.
Indiana Senate panel advances bill loosening medical prior authorizations
The bill would would prohibit health insurers from requiring prior authorization for routine medical services, federally approved prescription drugs, emergency health care and other services.
Odd bedfellows Mike Braun and Bernie Sanders team up to support health price transparency
The conservative Braun and the liberal Sanders might have more in common that meets the eye, with a growing list of issues they have both supported.
Health-tech startup DecisionRx lands $100M credit facility to fund growth
Indianapolis-based DecisionRx uses technology to recommend medication decisions to physicians and pharmacists based on genetic profiles, existing medication regimes and contraindications.
Riley Children’s Foundation sets up nutrition research partnership with $2.5M gift from Lilly CEO’s foundation
In addition, the Ricks Family Foundation says it will match up to an additional $2.5 million in donations from individuals, foundations and corporations.
Report: Indiana lagging nation in life sciences sector growth
Indiana’s pharmaceutical and medical device sectors, long touted as major contributors to the state’s economy, are starting to lag the nation in growth and market share and will require a focused effort to stay competitive, according to a new report released Monday.
Elevance Health buys Texas-based chain of infusion centers
Paragon Healthcare Inc., based in suburban Dallas, serves more than 35,000 patients with a broad range of acute and chronic conditions at more than 40 ambulatory infusion centers across eight southern and western states, as well as in patients’ homes.
Nevada company sues Lilly for breach of contract over Alzheimer’s drug
Lilly called the lawsuit “baseless” and said PDL BioPharma “has no plausible claim to royalties” for donanemab, which is expected to be approved by the FDA this quarter.
2023 Newsmaker: Ricks leads Lilly to new heights
David Ricks led Eli Lilly and Co. to milestone after milestone in 2023, with a slew of product launches for diseases from obesity to inflammatory bowel disease. And when Lilly wasn’t scoring wins in the laboratory, it was issuing a series of head-turning announcements,
Lilly’s soaring stock, Fishers’ innovation park among top 10 life sciences stories of 2023
It was a busy year for the Indiana life sciences community, with a flurry of billion-dollar deals, major announcements, and a few setbacks. Here we present the top 10 stories of 2023—the good, the bad and the ugly—about an industry that is often hailed as a key driver of Indiana’s economy.
RayzeBio Inc. to be acquired by drugmaker Bristol Myers Squibb for $4.1B
RayzeBio is building a large factory on the northwest side of Indianapolis to make radioisotopes for cancer treatment.
Made in Indiana: Chevrolet Silverado pickup trucks by General Motors
History: The Chevrolet Silverado, the second-most-popular pickup truck in America last year, is made at General Motors Co.’s Fort Wayne Assembly Plant. The 3-million-square-foot facility was built in 1986 and today employs nearly 4,000 people. GM has invested $1.2 billion in the plant, which recently celebrated manufacturing its 10 millionth truck. In June, GM announced […]
Lilly signs another AI deal, this one for obesity
Fauna Bio, based in the San Francisco area, said Thursday it will give Lilly access to its AI platform, called Convergence, to support preclinical drug discovery efforts in obesity.
Carmel firm raises $116M to advance anti-inflammatory drugs into human testing
The investment in Sudo Biosciences, a three-year-old Carmel biotech, is one of the largest in recent years for an Indiana-based science startup, a signal that investors are attracted by its work on a class of drugs to treat autoimmune and inflammatory diseases.
Community Health agrees to pay $345M to settle ‘false claims’ lawsuit
Community Health Network has agreed to pay the United States government $345 million to settle allegations that it engaged in a years-long scheme to recruit physicians and pay them huge salaries and bonuses in return for “downstream referrals” on medical procedures.
Point Biopharma shares sink 11% on study results; Lilly acquisition still up in air
Results of a clinical trial for Point Biopharma’s lead compound fell short of analysts’ expectations, and that development is likely to pressure its investors to decide whether to agree to sell the company to Eli Lilly and Co. for $1.4 billion.
Walgreens closes medical clinics in Indiana, causing headaches for patients and doctors
VillageMD, a subsidiary of Chicago-based pharmacy giant Walgreens Boots Alliance, is closing more than 60 primary care clinics in five markets, including nine practices in northern Indiana and four in central Indiana.
Lilly launches obesity drug, but insurers balk over price
The new drug, called Zepbound, carries a hefty price of $1,059.87 per month, and insurers and health care plans are balking, questioning its affordability. Many employers and government health programs exclude obesity treatments from their coverage.